{"id":"femoston-1-femoston-2","safety":{"commonSideEffects":[{"rate":null,"effect":"Breast tenderness"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vaginal bleeding or spotting"},{"rate":null,"effect":"Abdominal discomfort"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Femoston delivers micronized 17β-estradiol (a bioidentical estrogen) combined with dydrogesterone (a synthetic progestin) in a sequential or continuous regimen. The estradiol component alleviates vasomotor symptoms and supports bone health, while dydrogesterone provides endometrial protection in women with an intact uterus, reducing the risk of endometrial hyperplasia and cancer.","oneSentence":"Femoston is a hormone replacement therapy combining estradiol and dydrogesterone to replace declining estrogen and progesterone in postmenopausal women.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:46:18.739Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Vasomotor symptoms of menopause (hot flushes, night sweats)"},{"name":"Postmenopausal osteoporosis prevention"},{"name":"Genitourinary symptoms of menopause"}]},"trialDetails":[{"nctId":"NCT05156814","phase":"PHASE4","title":"Comparative Study to Evaluate the Efficacy and Safety of the Fixed-dose Combination of Estradiol / Dydrogesterone in Perimenopausal Women","status":"UNKNOWN","sponsor":"Scientific Research Institute of Public Health, Russian Federation","startDate":"2021-11-29","conditions":"Perimenopausal Disorder, Hot Flashes","enrollment":150},{"nctId":"NCT02264743","phase":"PHASE4","title":"Oral Verses Patch Trial In Menopausal Women - Individualisation of Oestrogen Therapy","status":"UNKNOWN","sponsor":"Royal Brompton & Harefield NHS Foundation Trust","startDate":"2013-11","conditions":"Venous Thrombosis, Insulin Resistance","enrollment":60},{"nctId":"NCT01300676","phase":"PHASE2, PHASE3","title":"The Effects of Tualang Honey on Postmenopausal Women","status":"COMPLETED","sponsor":"Universiti Sains Malaysia","startDate":"2009-03","conditions":"Postmenopausal Syndrome","enrollment":79}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Femoston® 1, Femoston® 2","genericName":"Femoston® 1, Femoston® 2","companyName":"Scientific Research Institute of Public Health, Russian Federation","companyId":"scientific-research-institute-of-public-health-russian-federation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Femoston is a hormone replacement therapy combining estradiol and dydrogesterone to replace declining estrogen and progesterone in postmenopausal women. Used for Vasomotor symptoms of menopause (hot flushes, night sweats), Postmenopausal osteoporosis prevention, Genitourinary symptoms of menopause.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}